Furthermore, the combination of HDAC inhibitors with PD-1 inhibitors has demonstrated the potential to reduce tumor growth rates and create a more favorable TME for cytotoxic T lymphocytes (92). The gene discussed is PDCD1; the disease is neoplasm.